Hatim Husain, MD, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer.
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discusses how National Comprehensive Cancer Network (NCCN) treatment guidelines adjust to meet the treatment needs of patients with lung cancer, including providing direction for molecularly guided therapies as new indications are approved.
Transcript
How have NCCN guidelines evolved as new targeted therapies for lung cancer have been approved?
NCCN guidelines have included new indications for new agents when appropriate. That list is expanding, with recent additions including KRAS, atypical EGFR variants with the exon 20 insertion, as well as additions in MET and also considerations for agents in development and kind of awaiting results, including HER2.
The NCCN has really been important in terms of including approved guidelines across a number of different new indications for molecularly guided therapies, as well as those which are emerging. And I think that’s an important consideration. Some of the emerging molecularly guided therapies that have been listed on the NCCN guidelines include MET inhibitors for copy number gain, or increased expression, as well as for HER2—specifically for HER2 mutations compared to protein expression or copy number gain that may be important in breast cancer.
The NCCN guidelines have evolved to include the approved agents for molecularly guided approaches, as well as emerging therapies, and give understandings about the applicability of those agents, specifically under circumstances where there is high MET amplification as well as HER2 mutations.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More